152 results on '"Houard, Sophie"'
Search Results
2. PA-435 Long-term immune response in children vaccinated with BK-SE36/CpG blood stage malaria candidate vaccine in a malaria hyperendemic and seasonal area of Burkina Faso
3. PA-463 Phase 1b randomized, controlled, double-blinded, age de-escalation trial to evaluate the safety, reactogenicity and immunogenicity of BK-SE36/CpG malaria vaccine in Burkinabe healthy adults and children
4. PA-658 Shigella incidence and resistance to commonly used antibiotics in children under five years of age living in a community setting in Ouagadougou, Burkina Faso
5. Contribution of the Rapid LAMP-Based Diagnostic Test (RLDT) to the Evaluation of Enterotoxigenic Escherichia coli (ETEC) and Shigella in Childhood Diarrhea in the Peri-Urban Area of Ouagadougou, Burkina Faso
6. Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses
7. Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial
8. Plasmodium falciparum infection coinciding with the malaria vaccine candidate BK-SE36 administration interferes with the immune responses in Burkinabe children
9. African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination
10. Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children
11. African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination.
12. Anti-HBs antibody persistence following primary vaccination with an investigational AS02V-adjuvanted hepatitis B vaccine in patients with renal insufficiency
13. Epitope Mapping and Fine Specificity of Human T and B Cell Responses for Novel Candidate Blood-Stage Malaria Vaccine P27A
14. Pipeline analysis of a vaccine candidate portfolio for diseases of poverty using the Portfolio-To-Impact modelling tool
15. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults
16. “Hairpin” and “hammerhead” ribozymes directed towards the Mumps virus nucleocapsid RNA: Specific cleavage of a small synthetic RNA substrate and full-length mRNA
17. First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria
18. Pipeline analysis of a vaccine candidate portfolio for diseases of poverty using the Portfolio-To-Impact modelling tool
19. The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes
20. OC 8546 SAFETY AND IMMUNOGENICITY OF THE MALARIA VACCINE CANDIDATE BK-SE36 IN YOUNG CHILDREN LIVING IN BURKINA FASO
21. OC 8489 CLINICAL DEVELOPMENT OF A THERAPEUTIC VACCINE FOR PREVENTION OF POST KALA AZAR DERMAL LEISHMANIASIS
22. First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria
23. Workshop report: Experimental animal models for universal influenza vaccines
24. Immunoassay standardisation for 'universal' influenza vaccines : Workshop report
25. The Candidate Blood-stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase 1 Trial in Exposed and Nonexposed Volunteers
26. Workshop report: Immunoassay standardisation for “universal” influenza vaccines
27. Candidate Blood-stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase 1 Trial in Exposed and Nonexposed Volunteers.
28. Clinical development of placental malaria vaccines and immunoassays harmonization:a workshop report
29. Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation
30. Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report
31. The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine
32. The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine
33. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency
34. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination results of two open, randomized, comparative trials
35. Immunogenicity and safety of an investigational AS02v-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: Results of two open, randomized, comparative trials
36. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02 V) in healthy adults
37. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02V-adjuvanted hepatitis B vaccine
38. Tissue factor: a mini-review.
39. Immunogenicity and safety of an investigational AS02v-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: Results of two open, randomized, comparative trials
40. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02V-adjuvanted hepatitis B vaccine
41. Engineering of non-conventional yeasts for efficient synthesis of macromolecules: The methylotrophic genera
42. Un vaccin contre les Paramyxoviridae :chimère ou réalité ?
43. Cloning, expression and purification of recombinant cotton rat interleukin-5.
44. Tissue factor: a mini-review
45. Cloning, expression and purification of recombinant cotton rat interferon-gamma.
46. Ribozyme-mediated decrease in mumps virus nucleocapsid mRNA level and progeny in infected vero cells
47. Immunosorbent assay based on recombinant Hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity
48. Tailing cDNAs with terminal deoxynucleotidyl transferase in RT-PCR assays to identify ribozyme cleavage products
49. Evaluation of hemagglutinin protein-specific immunoglobulin M for diagnosis of measles by an enzyme-linked immunosorbent assay based on recombinant protein produced in a high-efficiency mammalian expression system
50. Engineering of non-conventional yeasts for efficient synthesis of macromolecules: the methylotrophic genera
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.